Matthew Brown Codiak Biosciences

Matthew worked three years at U.S. F.D.A. researching downstream bioprocessing technologies specific to viral clearance, anti-HCP Reagents, and mycoplasma. He also worked four years at Boehringer Ingelheim on a continuous bioprocessing system with a focus on downstream technologies and viral safety strategy. This included developing and implementing a continuous viral inactivation chamber. Currently he is employed for one year at Codiak Biosciences that produces the novel modality, exosomes.